What is Merck & Co.'s SG&A?

Merck & Co. (MRK) reported SG&A of $2.7B in Q1 2026.

How has Merck & Co.'s SG&A changed year-over-year?

Merck & Co.'s SG&A increased by 5.8% year-over-year, from $2.55B to $2.7B.

What is the long-term trend for Merck & Co.'s SG&A?

Over 4 years (2021 to 2025), Merck & Co.'s SG&A has grown at a 2.7% compound annual growth rate (CAGR), from $9.63B to $10.73B.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Merck & Co. MRK SG&A

SG&A at other companies

Bristol-Myers SquibbBMY

$1.62B+2.1%

PfizerPFE

$2.96B-2.3%

Johnson & JohnsonJNJ

$6.03B+18.0%

Regeneron PharmaceuticalsREGN

$647.7M+2.3%

Phibro Animal HealthPAHC

$81.02M+14.0%

CytokineticsCYTK

——

Other financials

Income statement

See full

Revenue$16.3B+4.9%

Gross profit$12.1B-0.2%

Net income-$4.2B-183%

EPS (diluted)-$1.72-186%

Balance sheet

See full

Cash & equivalents$5.4B-38.2%

Total debt$49.1B+35.8%

Total equity$45.9B-5.1%

Total assets$128.69B+11.8%

Cash flow

See full

Operating cash flow$3.9B+56.7%

CapEx$991.0M-25.4%

Free cash flow$2.9B+150%

Valuation

See full

Market cap$309.84B+56.1%

Enterprise value$353.54B+56.5%

P/E34.7×+23.3×

P/S4.7×+1.6×

Profitability

See full

Gross margin73.9%-2.5pp

Net margin13.6%-13.7pp

FCF margin21.5%-5.2pp

Returns & leverage

See full

Return on equity19%-20.3pp

Debt / equity1.1×+0.3×

Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Merck & Co.'s SG&A?: Merck & Co. (MRK) reported SG&A of $2.7B in Q1 2026.
How has Merck & Co.'s SG&A changed year-over-year?: Merck & Co.'s SG&A increased by 5.8% year-over-year, from $2.55B to $2.7B.
What is the long-term trend for Merck & Co.'s SG&A?: Over 4 years (2021 to 2025), Merck & Co.'s SG&A has grown at a 2.7% compound annual growth rate (CAGR), from $9.63B to $10.73B.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.